Invited Lecture delivered by Dr Sujoy Dasgupta in a CME, sponsored by Serum Institute of India Pvt Ltd in the Convocation Ceremony of Interns at Sagor Dutta Medical College
PANEL DISCUSSION ON ENDOMETRIOSIS RELATED INFERTILITY (EVIDENCE BASED)Lifecare Centre
PANEL DISCUSSION ON ENDOMETRIOSIS RELATED INFERTILITY (EVIDENCE BASED)
MODERATOR
DR SHARDA JAIN
DR JYOTI AGARWAL
DR ILA GUPTA
UMA RAI
RAJ BOKARIA
JYOTI AGARWAL
JYOTI BHASKER
RENU CHAWLA
DIPTI NABH
VANDANA GUPTA
Invited Lecture delivered by Dr Sujoy Dasgupta in the Annual Conference of ISAR (Indian Society of Assisted Reproduction) held at Kolkata in November, 2019
Invited Lecture delivered by Dr Sujoy Dasgupta in a CME, sponsored by Serum Institute of India Pvt Ltd in the Convocation Ceremony of Interns at Sagor Dutta Medical College
PANEL DISCUSSION ON ENDOMETRIOSIS RELATED INFERTILITY (EVIDENCE BASED)Lifecare Centre
PANEL DISCUSSION ON ENDOMETRIOSIS RELATED INFERTILITY (EVIDENCE BASED)
MODERATOR
DR SHARDA JAIN
DR JYOTI AGARWAL
DR ILA GUPTA
UMA RAI
RAJ BOKARIA
JYOTI AGARWAL
JYOTI BHASKER
RENU CHAWLA
DIPTI NABH
VANDANA GUPTA
Invited Lecture delivered by Dr Sujoy Dasgupta in the Annual Conference of ISAR (Indian Society of Assisted Reproduction) held at Kolkata in November, 2019
Dr Sujoy Dasgupta moderated a Panel Discussion on "Difficult cases in IUI" in the Annual Conference of ISAR (Indian Society of Assisted Reproduction), Bengal held in December, 2022
Management of Endometrioma- Current UpdateSujoy Dasgupta
Invited Lecture by Dr Sujoy Dasgupta in the Webinar on "Update on Endometriosis" organized by AICC RCOG (All India Coordinating Committee of Royal College of Obstetricians and Gynaecologists) East Zone, held in December, 2021
ESHRE Guideline on Recurrent Pregnancy Loss (RPL)Sujoy Dasgupta
Dr Sujoy Dasgupta invited to deliver a lecture on "RPL- ESHRE Guideline" in the Annual Conference of RCOG (Royal College of Obstetricians and Gynaecologists) IRC (International Representative Committee) India East held on 20-21 May, 2023
Antagonist - Tips and tricks to optimize use in Intra Uterine Insemination (I...Anu Test Tube Baby Centre
Presentation given in 2017. Management of infertility using assisted reproductive technologies.
What is the role of antagonist in IUI and IVF - tips and tricks to optimize its use.
Since the first formal description of LPD in 1949 as a possible cause of infertility and recurrent miscarriage by Jones. Innumerable investigations have been undertaken in an effort to verify its existence or to characterize its pathophysiology, diagnosis, and treatment. The consensus of the literature is that LPD does exist and that its cause is multifactorial like abnormal folliculogenesis, inadequate LH surge,inadequate secretion of progesterone by the corpus luteum, aberrant end-organ response by the endometrium.
Dr Sujoy Dasgupta was invited to deliver a lecture at the Conference of IMA (Indian Medical Association), held at July 2019 in Kolkata. This session was sponsored by Meyer Organic.
Dr Sujoy Dasgupta moderated a Panel Discussion on "Difficult cases in IUI" in the Annual Conference of ISAR (Indian Society of Assisted Reproduction), Bengal held in December, 2022
Management of Endometrioma- Current UpdateSujoy Dasgupta
Invited Lecture by Dr Sujoy Dasgupta in the Webinar on "Update on Endometriosis" organized by AICC RCOG (All India Coordinating Committee of Royal College of Obstetricians and Gynaecologists) East Zone, held in December, 2021
ESHRE Guideline on Recurrent Pregnancy Loss (RPL)Sujoy Dasgupta
Dr Sujoy Dasgupta invited to deliver a lecture on "RPL- ESHRE Guideline" in the Annual Conference of RCOG (Royal College of Obstetricians and Gynaecologists) IRC (International Representative Committee) India East held on 20-21 May, 2023
Antagonist - Tips and tricks to optimize use in Intra Uterine Insemination (I...Anu Test Tube Baby Centre
Presentation given in 2017. Management of infertility using assisted reproductive technologies.
What is the role of antagonist in IUI and IVF - tips and tricks to optimize its use.
Since the first formal description of LPD in 1949 as a possible cause of infertility and recurrent miscarriage by Jones. Innumerable investigations have been undertaken in an effort to verify its existence or to characterize its pathophysiology, diagnosis, and treatment. The consensus of the literature is that LPD does exist and that its cause is multifactorial like abnormal folliculogenesis, inadequate LH surge,inadequate secretion of progesterone by the corpus luteum, aberrant end-organ response by the endometrium.
Dr Sujoy Dasgupta was invited to deliver a lecture at the Conference of IMA (Indian Medical Association), held at July 2019 in Kolkata. This session was sponsored by Meyer Organic.
Endometriosis and fertility how and when to treatDr Aditya Keya
Endometriosis can influence fertility in several ways: distorted anatomy of the pelvis, adhesions, scarred fallopian tubes, inflammation of the pelvic structures, altered immune system functioning, changes in the hormonal environment of the eggs, impaired implantation of a pregnancy, and altered egg quality.
The Newer Concepts forReduced Surgery to preserve fertility in Endometrios...Lifecare Centre
The Newer Concepts forReduced Surgery to preserve fertility in Endometriosis
ENDOMETRIOSIS IS ENIGMA
DIAGNOSTIC DILEMMA
DEBILITATING DISEASE QOL
PROGRESSIVE DISEASE
RECURRENCE IS BIG PROBLEM
NO FINAL VERDICT ON CAUSE
NO PERMANENT CURE
The exact prevalence of endometriosis is unknown, but estimates 10% in the general female population in India but up to 50% in infertile women
AGAINST the Motion- “Surgery is the ONLY treatment of Endometriosis with Infe...Sujoy Dasgupta
Dr Sujoy Dasgupta participated in an invited debate through a webinar organized by Dr B. N. Chakraborty School of Fertility Management and research, held in July, 2020
Recurrence of endometriosis is fairly common; some studies suggest the rate of recurrence to be as high as 40%. Most common cause of recurrence is incomplete resection in primary surgery and microscopic foci which escapes detection.
AGAINST the Motion- “Surgery is the ONLY treatment of Endometriosis with Infe...Sujoy Dasgupta
Dr Sujoy Dasgupta participated in the invited debate on “Surgery is the ONLY treatment of Endometriosis with Infertility” in the Webinar organized by the AICC RCOG (All India Coordinating Committee) East Zone held in February, 2022
Endometriosis is known to have a remarkably negative effect on the Quality of Life of the women. Surgery is considered when medical therapy is unsuccessful or in the setting of infertility. A high recurrence rate is reported in advanced stages of endometriosis. Thus, Complete excision and prevention of recurrence is particularly important.
Endometriosis and Subfertility - What to do?Sujoy Dasgupta
Lecture delivered by Dr Sujoy Dasgupta in IPCON 2823, the Mid term conference of ISOPARB (Indian Society of Perinatology and Reproductive Biology) held at Kolkata on 10 September
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Dr Sujoy Dasgupta was invited to deliver a lecture on "Male Infertility, Antioxidants and Beyond" on 3 February in Yuvacon 2024 organized by the Bengal Obstetric and Gynaecological Society (BOGS). The session was supported by UNS.
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
Dr Sujoy Dasgupta participated in an invited debate FOR the motion "Radical excision of DIE in subferile women with deep infiltrating endometriosis is not recommended" in ENDOGYN 2024, organized by the IAGE (Indian Association of Gynaecological Endoscopists) and the BOGS (Bengal Obstetric and Gynaecological Society) on 10 February 2024.
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
Invited lecture by Dr Sujoy Dasgupta in the Ultrasound Workshop of the Annual National Conference of Indian Association of Gynaecological Endoscopists (IAGE) held on 15 March 2024 at the Taj Ganges, Varanasi
Invited lecture by Dr Sujoy Dasgupta on "Azoospermia - Evaluation and Management" in a CME on "Standardising Male Factor Evaluation" organised by Indian Fertility Society (IFS) on 20 January 2024.
Are we giving much importance to AMH in infertility practice?Sujoy Dasgupta
Dr Sujoy Dasgupta delivered "Kamini Rao Oration" on "Are we giving much importance to AMH in infertility practice?" in East Zone Yuva FOGSI Conference organized by Imphal Obstetric and Gynaecological Society (IOGS) on 24 December, 2023
Male Infertility-How a Gynaecologist can Manage?Sujoy Dasgupta
Dr Sujoy dasgupta delivered an invited lecture on "Male Infertility-How a Gynaecologist can Manage?" in a CME on "New Frontiers in Infertility" organized by Genome Fertility Centre and Bhagirathi Neotia Woman and Child Care Centre, Kolkata held on 15 December 2023
Endometriosis and Subfertility, Primium non nocereSujoy Dasgupta
Dr Sujoy dasgupta and Dr Arun Madhab Barua were invited to moderate a panel discussion on "Endometriosis and Subfertility, Primium non nocere" in the International Congress on Endometriosis (ICE) on 10 December 2023 at Dhana Dhanya Auditorium, Kolkata
Dr Sujoy Dasgupta delivered an invited talk on "Embryo Transfer" in "Ultrasound Workshop" on 8 December 2023 at Milan, 2023, the conference of all the Obstetric and Gynaecological Societies of West Bengal. This conference was organized by Kalyani Obstetric and Gynaecological Society (KOGS).
Rational Investigations and Management of Male InfertilitySujoy Dasgupta
Dr Sujoy Dasgupta delivered an invited lecture in the annual conference of WMOGS (West Midnapore Obstetric and Gynaecological Society) held on 16 September, 2023
IVF- How it changed the perspective of Male InfertilitySujoy Dasgupta
Dr Sujoy Dasgupta was invited to deliver a talk in a CME held on the World IVF Day (25 July, 2023) organized by Burdwan Obst Gynae Society and Corona Remedies.
Male Infertility- How Gynaecologists can manage?Sujoy Dasgupta
Dr Sujoy Dasgupta delivered an invited lecture in a CME organised by JB Pharma with the support from West Midnapore Obst and Gynae Society and Genome Fertility Centre held at Medinipur on 22 July, 2023.
Role of Multivitamins & Antioxidants in Managing Male Infertility Sujoy Dasgupta
Dr Sujoy Dasgupta was invited to deliver a talk on "Role of Multivitamins & Antioxidants in Managing Male Infertility " in a CME organized by Agartala Obstetric and Gynaecological Society and ArEx Laboratory held at Agartala on 8 July 2023
Panel discussion moderated by Dr Sujoy Dasgupta and Dr Sudip Basu on "Troubleshooting in Male Subfertility" in the Andrology Workshop organized by Special Interest Group (SIG) Andrology and Indian Fertility Society (IFS) West Bengal Chapter held on 11 June 2023 at Kolkata
Fertility Management: Synergy between Endoscopists and Fertility SpecialistsSujoy Dasgupta
Dr Sujoy Dasgupta was invited to moderate a panel discussion on "Fertility Management: Synergy between Endoscopists and Fertility Specialists " in a CME by Torrent held on 27 May 2023.
Invited lecture by Dr Sujoy Dasgupta on "Abnormal Semen- What Next" in a CME organized by HBC Life Sciences on "Fertility and Beyond" held on 28 April 2023
Oration delivered by Dr Sujoy Dasgupta at Yuvacon, conference organized by the BOGS (Bengal Obstetric and Gynaecological Society) held on 22-23 April, 2023
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
1. Sujoy Dasgupta
MBBS (Gold Medalist, Hons)
MS (OBGY- Gold Medalist)
DNB (New Delhi)
MRCOG (London)
Advanced ART Course for Clinicians (NUHS, Singapore)
Consultant: Reproductive Medicine, Genome Fertility Centre, Kolkata
Managing Committee Member, Bengal Obstetric & Gynaecological Society (BOGS)
Secretary, Subfertility and Reproductive Endocrinology Committee, BOGS
Executive Committee Member, Indian Fertility Society (IFS)- West Bengal Chapter
Executive Committee Member, Indian Society for Assisted Reproduction (ISAR)- Bengal
Member, Endocrinology Committee, Federation of Obstetric and Gynaecological Societies of
India (FOGSI)
Convener and Faculty, Spectrum MRCOG Course
Winner, Prof Geoffrey Chamberlain Award, RCOG World Congress, London, 2019
Management of Infertility in
Endometriosis
2. ENDOMETRIOSIS is a
chronic, estrogen-
dependent, inflammatory,
painful disorder in which
endometrial tissue grows
outside the uterus.
3. Types of Endometriosis
• Peritoneal endometriosis
They are endometriotic implants on the surface of the surface of pelvic
peritoneum and ovaries.
• Endometriomas
They are ovarian cysts lined by endometrioid mucosa.
• Rectovaginal endometriotic nodules
It is a complex solid mass comprised of endometriotic tissue blended
with adipose and fibromuscular tissue, residing between the rectum and
the vagina.
•Adenomyosis (Endometriosis Interna)
Endometriosis in the myometrium (Musculature of the uterus)
•Extragenital endometriosis
Scar tissue, pleura, omentum, lungs, limbs
4. • Occurs in 6–10% of women of reproductive
age
• with a prevalence of 38% in infertile women,
and
• in 71–87% of women with chronic pelvic pain
• The Endometriosis Society of India estimates
that 25 million i.e about 35% Indian women
suffer from this condition.
5. 1. Endometriosis may be a diagnosis of
exclusion
2. A significant number of women with
endometriosis remain asymptomatic
Therefore, DIAGNOSIS of endometriosis in a
woman with pelvic pain is often delayed &
stretches over several years!
6.
7. Diagnosis Of Endometriosis
Clinicians should consider the
diagnosis of endometriosis
in the presence of gynecological
symptoms-
Dysmenorrhea
non-cyclical pelvic pain
deep dyspareunia
Infertility
fatigue
in women of reproductive age with
non-gynecological cyclical symptoms
Dyschezia
rectal bleeding
Dysuria
Hematuria
shoulder pain
9. Diagnosis of Endometriosis
• Clinical examination
• CA-125
• TVS
• MRI
• Laparoscopy
• Do not exclude the
possibility of
endometriosis if the
abdominal or pelvic
examination, ultrasound
or MRI are normal. If
clinical suspicion
remains or symptoms
persist, consider referral
for further assessment
and investigation. (NICE,
2017)
10. Advanced Imaging
• Do not systematically
request second-level
diagnostic investigations
in women with known or
suspected non-occlusive
colorectal endometriosis
or with symptoms
responding to medical
treatment (quality of the
evidence, low; weak
suggestion)
11. Gold Standard
•The combination of laparoscopy and the histological verification of
endometrial glands and/or stroma
•In many cases the typical appearances of endometriotic implants
in the abdominal cavity are regarded as proof that endometriosis is
present.
•A negative diagnostic laparoscopy (i.e. a laparoscopy during which
no endometriosis is identified) seems to be highly accurate for
excluding endometriosis and is therefore of use to the clinician in
aiding decision-making. (ESHRE, 2013)
12. Standard procedure
A good quality laparoscopy should include systematic checking of
•1) the uterus and adnexa,
•2) the peritoneum of ovarian fossae, vesico-uterine fold, Douglas and
pararectal spaces,
•3) the rectum and sigmoid (isolated sigmoid nodules),
•4) the appendix and caecum and
•5) the diaphragm.
•6) speculum examination and palpation of the vagina and cervix under
laparoscopic control, to check for 'buried' nodules.
•A good quality laparoscopy can only be performed by using at least
one secondary port for a suitable grasper to clear the pelvis of obstruction
from bowel loops, or fluid suction to ensure the whole pouch of Douglas
is inspected.
•By a gynaecologist with training and skills in laparoscopic surgery for
endometriosis
13. Biopsy
to confirm the diagnosis of endometriosis
(be aware that a negative histological result
does not exclude endometriosis)
to exclude malignancy
1. if an endometrioma is treated but not excised
2. deep infiltrating disease
14. Stage 1: Lesions are
minimal & isolated
Stage 2: Lesions are mild -
may be several; adhesions
are possible.
Stage 3: Lesions are
moderate, deep or
superficial with clear
adhesions
Stage 4: Lesions are
multiple & severe, both
superficial & deep, with
prominent adhesions.
ASRM
classification of
endometriosis
15. Staging of Endometriosis
• Does not correlate well with the symptoms of
pain or fertility.
• Offer endometriosis treatment according to the
woman's symptoms, preferences and priorities,
rather than the stage of the endometriosis.
*NICE, 2017
17. There is NO permanent cure for
endometriosis
• No single treatment is ideal for all patients, management
chosen should be directed to individual needs of each patient
• Combination therapy may be ideal; as it is a chronic disease,
we should consider not only efficacy but also long-term safety
and tolerability of treatment options.
• Long-term treatment / repeated courses owing to frequent
recurrence of pain within 6-12 months of completing
treatment course (within 5 years in about half of women)
18. Patient's age
Pain symptoms
Extent of disease
Patient's
reproductive
plans
Treatment risks
Side effects
Cost
considerations
CHOICE OF
TREATMENT
19. Subfertility is “Couple’s” problem
Unexplained
10%
Endometriosis
25%
Tubal Factor
15%
Ovulation
20%
Male Factor
30%
Diagnosis
20. Endometriosis and Infertility
• Dysparaeunia
• Distorted Pelvic Anatomy.
• Altered Peritoneal Function.
• Hormonal and Ovulatory Abnormalities.
• Impaired Implantation (challenged based on b-3
integrin research)
• Oocyte and Embryo Quality.
• Abnormal Uterotubal Transport.
21. Subfertility
• About 1/3rd of women with endometriosis also suffer
from subfertility.
• Endometriosis does not equal infertility. It just implies that
some women may have a harder time becoming pregnant.
• Once the endometriosis is treated then women can usually
conceive naturally without any assisted reproductive
techniques.
22. Endometriosis-Infertility:
Basic principles of management
• Medical management is not possible
• Medical management does NOT improve the
chance of conception (except: GnRH Ago in IVF)
• Laparoscopy confirms the severity of
endometriosis
• Laparoscopy improves pain
• Laparoscopy improves chance of natural
conception
• Laparoscopy does NOT improve the success of
IVF
23. Case 1
• Mrs AB, P0+0, trying to conceive for one year.
She is having severe dysmenorrhoea not
responding to NSAID.
• Husband’s semen, HSG, AMH all are normal
24
24. Medical therapy
Hormonal therapies
•Pregnancy is not
possible/contraindicated during
hormonal therapy
•Hormonal treatment for
suppression of ovarian function
does not improve the chance
of natural conception
•Only indicated- if wants to
delay Laparoscopy/ IVF and
the pain is severe
Analgesics
• NSAIDs should be avoided
around the time of
ovulation
26. Surgery for Peritoneal
Endometriosis
• Both ablation and excision improve the chance
of spontaneous conception in ASRM stage I/II
endometriosis (CO2 laser vaporization >
monopolar electrocoagulation)
• Complete surgical removal before ART- ?
27. Surgery for ovarian endometrioma
• Cystectomy improves the chance of spontaneous
conception, but NOT the success of ART
• A small added risk of requiring an oophorectomy
• clinicians counsel regarding the risks of reduced ovarian
function after surgery and the possible loss of the ovary.
The decision to proceed with surgery should be considered
carefully if the woman has had previous ovarian surgery.
• Preoperative assessment of ovarian reserve
• Management should be individualised
28. Which Surgery
(ESHRE 2013, RCOG 2017, NICE 2017)
Compared with drainage and coagulation,
Cystectomy is associated with
• an overall lower recurrence risk
• decreased pain
• higher spontaneous postoperative pregnancy rate,
• particularly if the cyst is ≥3 cm in diameter. (OR
5.24, 95% CI 1.92–14.27; n = 88; two trials)
[Cochrane Database Syst Rev
2008;(2):CD004992]
29
29. Surgery for deep endometriosis
In women with infertility and severe pelvic pain who
are resistant to medical treatment or severe bowel
stenosis,
radical excision of endometriosis combined with
bowel segmental resection and anastomosis was
associated with a higher postoperative spontaneous
pregnancy rate
30. 1. 3-10% chances of damaging
the surrounding organs-
bladder, bowel, ureter, nerves
2. Risk of oophorectomy.
3. Complete excision of
endometriotic tissue not
possible.
4. May not reverse the
inflammatory and
biomolecular changes shown
to influence fertilisation and
implantation.
5. Needs skill
*Vercellini et al., 2009; Lebovic, 2016
31. Case 1 (Contd.)
• Mrs AB underwent laparoscopy
• ovarian cystectomy (4 cm), adhesiolysis and
ablation of superficial peritoneal endometriosis
were done.
• Tubal patency was confirmed B/L.
32
32. Next Step
• GnRh Agonist/ Dienogest- Post op?
• Do not prescribe adjunctive hormonal
treatment after surgery, in women trying for
pregnancy (ESHRE, 2013)
33. Case 2
• Mrs PC, 32, trying for pregnancy for 1 year.
• All investigations (Semen, AMH, HSG)
normal.
• 2 cm endometrioma in left ovary.
• No pain.
34. Conservative management for spontaneous
conception
Encourage to try natural conception before seeking fertility treatment-
1. Young women,
2. regular menstrual cycles and
3. an incidental finding of an ovarian endometrioma
4. without suspicion of malignancy
•43% spontaneous pregnancy rate during the 6-month follow up period
•Similar ovulation rates in the affected ovary to the healthy ovary
*Benaglia et al., 2009; Leone Roberti Maggiore et al., 2015; RCOG, 2017
35
35. Case 2 (Contd)
• Mrs PC returns after 6 months after trying 5
cycles of ovulation induction.
• She is interested in IUI
38. Limitations of IUI in endometriosis
• Hughes, 1997- Meta-analysis- IUI success is halved in
stage I/II endometriosis
• Gandhi et al., 2014- No difference between expectant
management and IUI
• Dmowski et al., 2002- first-cycle chance of pregnancy
with IVF is significantly higher than the cumulative
pregnancy rate after 6 IUI cycles
• IVF, but not IUI, can be expected to overcome the
detrimental effects of a pelvic inflammatory milieu.
• Van der Houwen et al., 2014; D’Hooghe et al., 2006-
the risk of endometriosis recurrence appears to be
increased by IUI (more than IVF)
39. Case 3
• Mrs PS, 28, trying for pregnancy for 3 years. She
had severe dysmenorrhoea, dyschezia and
dysuria.
• There was 5 cm unilateral endometrioma and
MRI scan suggested the possibility of
rectosigmoid endometriosis.
• AMH 2.3 ng/ml, husband’s semen normal, tubes
not checked
• She wanted to defer surgery for 4 months because
of professional commitments
40. Preoperative hormonal therapies
Furness S, Yap C, Farquhar C and Cheong YC. Pre and post-operative medical therapy
for endometriosis surgery. Cochrane Database Syst Rev 2004:CD003678. [New search
for studies, and content updated (no change to conclusions), published in Issue 1, 2011.]
Clinicians should not prescribe preoperative hormonal treatment to improve the
outcome of surgery for pain in women with endometriosis
•In clinical practice, surgeons prescribe preoperative medical treatment with GnRH
analogues as this can facilitate surgery due to reduced inflammation, vascularisation of
endometriosis lesions and adhesions. However, there are no controlled studies supporting
this (ESHRE, 2013)
•Consider GnRH agonist x 3 cycles before surgery for deep infiltrating endometriosis
(NICE, 2017)
• From a patient perspective, medical treatment should be offered before surgery to
women with painful symptoms in the waiting period before the surgery can be
performed, with the purpose of reducing pain before, not after, surgery.
41. Case 2 (Contd)
• Mrs PS’s laparoscopy suggested grade IV
endometriosis
• Adhesiolysis could not be done
• Tubes and ovaries difficult to identify
• Tubal patency- Right- slow spill, Left- no spill
42
45. Surrey ES. "Endometriosis-Related Infertility: The Role of the Assisted
Reproductive Technologies", BioMed Research International, 2015
46. Georgiou EX, Melo P, Baker PE, Sallam HN, Arici A, Garcia‐Velasco JA, Abou‐Setta AM,
Becker C, Granne IE. Long‐term GnRH agonist therapy before in vitro fertilisation (IVF) for
improving fertility outcomes in women with endometriosis. Cochrane Database of Systematic
Reviews 2019, Issue 11. Art. No.: CD013240. DOI: 10.1002/14651858.CD013240.pub2
• In light of the paucity and very low quality of
existing data, particularly for the primary
outcomes examined, further high‐quality trials
are required to definitively determine the impact
of long‐term GnRH agonist therapy on IVF/ICSI
outcomes, not only compared to no pretreatment,
but also compared to other proposed alternatives
to endometriosis management
47. Muller V, Kogan I, Yarmolinskaya M, Niauri D, Gzgzyan A, Aylamazyan E.
(2017). Dienogest treatment after ovarian endometrioma removal in infertile
women prior to IVF, Gynecological Endocrinology, 33:sup1, 18-21,
48. Tamura, H., Yoshida, H., Kikuchi, H. et al. The clinical outcome of Dienogest treatment
followed by in vitro fertilization and embryo transfer in infertile women with endometriosis. J
Ovarian Res 12, 123 (2019).
• No significant difference in the implantation and
miscarriage rates between the groups
• The cumulative pregnancy rate and live birth rate were
lower in the DNG group than in the control group.
49. GnRH Ago in IVF for endometriosis
1. Ultra-long protocol
2. Antagonist protocol → OPU → Freeze all →
GnRH Ago (3-6) → FET
Antagonist protocol may not be inferior to
agonist protocol (ESHRE, 2013)
50. Case 3 (Contd)
• Mrs PS was referred for IVF.
• She received 2 doses of injection (Leuprolide
acetate depot 3.75) IM before referral to the
IVF clinic
51. She does not want to defer IVF
anymore
• Start stimulation, utilizing the long agonist
protocol
52. Case 4
• Mrs FR, 32 years, has been trying for
pregnancy for last 2 years. AMH, AFC, HSG
all normal.
• Husband is having azoospermia. Donor sperm
is no acceptable.
• 6 cm right ovarian endometrioma, minimum
dysmenorrhoea
53
53. Option
• TESA-ICSI
• Laparoscopy if cyst size
increases/ pain/ difficult
OPU
• Evaluate
1. Cyst location
2. Accessibility of the
follicles
3. AFC
54
54. Endometrioma and IVF Outcome
• Endometrioma compared with no endometriosis,
1. ovarian response was lower, with a lower number of oocytes
retrieved (mean difference –0.23; 95% CI 0.37–0.1)
2. a higher cancellation rate (OR 2.83; 95% CI 1.32–6.06)
3. Higher gonadotropin consumption
4. live birth (OR 0.98; 95% CI 0.71–1.36), pregnancy (OR
1.17; 95% CI 0.87–1.58) and miscarriage rates (OR 1.7;
95% CI 0.86–3.35) were similar [Fertil
Steril, 2012]
• Endometrioma vs other areas of endometriosis
- IVF outcomes (live birth, pregnancy, miscarriage and cycle
cancellation rates, and mean number of oocytes retrieved) were
similar [Hum Reprod Update 2015]
55
55. Surgery prior to IVF
• Lowers serum AMH levels further
• Progressive decline in ovarian reserve
• Higher gonadotrophin consumption
• Lower number of oocyte retrieved
*Raffi et al., 2012; Somigliana et al., 2012; Sugita et al., 2013; Hamdan et al.,
2015; Polyzos and Sunkara, 2015; Brink Laursen et al., 2017; Tao et al., 2017;
Nickkho-Amiry et al., 2018
58. Complications during and after OPU
• Technical difficulties during oocyte retrieval is low,
• No data to suggest that surgery will prevent adhesion reformation
and facilitate oocyte retrieval effectively.
• Risks of infection from an endometrioma (0–1.9%)
• Follicular fluid contamination (2.8–6.1%)
• Progression of pelvic endometriosis and ovarian
endometriomas- ?
*Koch et al., 2012; RCOG, 2017
59. Risk of missing malignancy
• Extremely low in endometrioma
• The lifetime probability of Ca ovary 1-2% in the
presence of an endometrioma.
• In the context of IVF treatment, delaying
surgery for a few months or years, until the
treatment has been completed or following
delivery, would usually be a reasonable course of
action unless there are other immediate
concerns.
*RCOG, 2017
60. Ultrasound-guided Aspiration
• Transvaginal USG-guided drainage
without surgery does not seem to be
effective.
• a high recurrence rate
• To decrease recurrence rate, aspiration is
combined with in situ injection of
tetracycline/ethanol/methotrexate
• Disadvantages:
Complications: infection, abscess
formation, and pain
inability to rule out any malignancy
risk of pelvic adhesion
61
61. Case 5
• Mrs DH, 37 years old has been trying for
pregnancy for last 6 months. Husband’s semen
normal, HSG not done. AMH 0.5 ng/ml
• She underwent left ovarian cystectomy 6 years
ago, no documents are available for that.
• She is having severe dysmenorrhoea, TVS
revealed AFC 2 (right) plus 3 (left) and 5 cm
chocolate cyst in right ovary
62
63. RCOG Recommendations (2017)
Directly ART
• Asymptomatic women,
• women of advanced
reproductive age,
• those with reduced
ovarian reserve,
• bilateral endometriomas
• a history of prior ovarian
surgery
Surgery before IVF
• highly symptomatic
women,
• with an intact ovarian
reserve,
• unilateral and large cysts,
• cysts with suspicious
radiological and clinical
features.
64
64. Case 5 (Contd)
• Mrs DH underwent IVF-ICSI. 2 good quality
of embryos (grade A) on day3 were transferred
after GnRH-Ago down regulation.
• Beta hCG negative !!!
65
65.
66. Molecular expression - Implantation
• Aromatase present in Endometrium of women with
endometriosis. (Noble et al 1995)
• B-3 integrin expression is aberrant in endometrium
of women with endometriosis (Lessey et al 1996)
Implantation Requires Synchrony
• Delayed implantation - leads to miscarriage
• Miscarriage goes up with each day of delay
• Clinical evidence for the window of implantation
67. French Study
63% Endometriosis
Eur J Obstet Gynecol Reprod Biol. 2012
Time to Treat
Undiagnosed Endometriosis
In
Unexplained Infertility
Leads to
Recurrent Implantation Failures
Belgium Study
47% endometriosis
Fertility & Sterility Vol. 92, 1, July 2009
68. Human Reproduction, Volume 27,
Issue 3, 1 March 2012
Systems Biology in Reproductive
Medicine, Volume 60, 2014
Letrozole improves the
marker of Endometrial Receptivity
Letrozole improves
Integrin expression in IVF
Letrozole improves
Integrin, LIF & L- Selectin
expression in natural cycle
Window of uterine receptivity remains open for an extended period
at lower estrogen levels but rapidly closes at higher levels
PNAS March 4, 2003 100 (5) 2963-296
69. Role of laparoscopy in IVF-Failure
and endoemtriosis
• Normal HSG, repeated IVF failure- 57% cases can have
endometriosis- surgical treatment improves outcome (Yu et
al., 2019)
• In symptomatic women with severe endometriosis-
surgery improves IVF outcome (Soriano et al., 2016)
• Need to do 40 laparoscopy to achieve a pregnancy (ASRM,
2012)
• Down-regulation with GnRH agonist and letrozole may be
useful in RIF patients without surgically proved
endometriosis (Moustafa and Young, 2020)
70. Case 6
• Mrs JK, 29 years with “unexplained infertility”
of 2 years duration.
• Tried multiple cycles of OI and IUI
• HSG, AMH, Semen all normal
• No dysmenorrhoea
• Role of laparoscopy to diagnose
endometriosis and treatment?
71
71. Unexplained Infertility
• Reflects an incomplete fertility evaluation
• 20-40% cases of unexplained infertility may be
because of undiagnosed endometriosis
*Hurt, 2003; Fadhlaoui et al., 2014
72.
73. Recent Studies on Endometriosis and
Unexplained Infertility
• RCTs- Parazzini, 1999; Gad and Badroui, 2012
• Meta-Analysis
Jacobson et al., 2010 Duffy et al., 2014
OR for ongoing pregnancy (95% CI) 1.64 (1.05– 2.57) 1.94 (1.20–3.16)
The number of infertile women that should
undergo destruction of superficial peritoneal
endometriosis
12 8
The prevalence of grade I/ II endometriosis among
women with unexplained infertility
≤50%
NNT 24 16
74. Recent Studies on Endometriosis and
Unexplained Infertility
• RCTs- Parazzini, 1999; Gad and Badroui, 2012
• Meta-Analysis
• Success rate of IVF - ∼25% (NNT- 4)
*European IVF-Monitoring Consortium (EIM) for ESHRE, 2016
Jacobson et al., 2010 Duffy et al., 2014
OR for ongoing pregnancy (95% CI) 1.64 (1.05– 2.57) 1.94 (1.20–3.16)
The number of infertile women that should
undergo destruction of superficial peritoneal
endometriosis
12 8
The prevalence of grade I/ II endometriosis among
women with unexplained infertility
≤50%
NNT 24 16
75. • Routine laparoscopy should NOT be done in
women with infertility without pelvic pain
(Quality of evidence- High)
• Consider surgery for superficial endometriosis
ONLY in women
1. Having moderate-severe pain
2. Seeking natural conception, declining ART
76. • In the absence of evidence for tubal or other pelvic
pathology, laparoscopy is NOT warranted in
unexplained infertility (Level II-2B).
77. Deep endometriosis - asymptomatic
• Uncommon to be asymptomatic
• Uncomplicated- If no symptoms of ureter/ bowel
stenosis- No need of surgery
• 9 out of 10 will not progress
• Improper resection will worsen bowel/ bladder
symptoms
Operate, ONLY when-
1. Occlusive disease (ureter/ bowel)
2. Wishing natural conception, declining IVF
*Dunselman et al., 2014; Berlanda et al., 2016; ETIC, 2018
78. Before final decision
• Pain
• Age and Ovarian reserve
• Previous surgery
• Male and tubal factor
• Patient’s wishes
81. Take Home
• Take into account overall fertility picture, age,
symptoms, previous surgery
• During Medical therapy pregnancy is NOT possible
• Medical therapy (ovarian suppression) does NOT
improve chance of natural conception
• Surgery improves pain, clarifies diagnosis
• Surgery improves the chance of natural conception
• Immediately after surgery- Best period to conceive
• Medical therapy will NOT compensate for
inadequate surgery
• Surgery does NOT improve the success rate of IVF
Editor's Notes
Up to 20% of women with endometriosis have concurrent chronic pain conditions, including irritable bowel syndrome, interstitial cystitis/painful bladder syndrome, fibromyalgia, and migraines
As I was telling you there is a years of gap between the onset of symptoms of pelvic pain and diagnosis of em
hypoestrogenic (GnRH agonist), hyperandrogenic (danazol, gestrinone) or hyperprogestogenic (oral contraceptives, medroxyprogesterone acetate) state that suppresses endometrial cell proliferation.